The only practical means of maintaining a raised output of steroids from the adrenal cortex is by the daily intramuscular or subcutaneous injection of corticotropin in a medium that delays absorption. The effects produced by such therapy depend upon -the amount by which the daily output of steroids is raised above the starting level and the length of time that the raised level is maintained. The only practical means of measuring the output of the adrenal cortex is by assaying, in 24-hr specimens of urine, the metabolites of the principal hormone cortisol (hydrocortisone). The study reported here covers 4+ years, and is a follow-up of a previous study (West and Newns, 1955). For the first 18 months the metabolites of cortisol were assayed by the "17-ketogenic steroid" (17 KGS) method (Norymberski, Stubbs, and West, 1953) and since then they have been assayed by the "total 17-hydroxycorticosteroid" (17(OH)CS) method (Appleby, Gibson, Norymberski, and Stubbs, 1955) . Both assays were developed at this Centre. The results of these two assays do not differ appreciably except in the rare disorders of the adrenal cortex.
The only practical means of maintaining a raised output of steroids from the adrenal cortex is by the daily intramuscular or subcutaneous injection of corticotropin in a medium that delays absorption. The effects produced by such therapy depend upon -the amount by which the daily output of steroids is raised above the starting level and the length of time that the raised level is maintained. The only practical means of measuring the output of the adrenal cortex is by assaying, in 24-hr specimens of urine, the metabolites of the principal hormone cortisol (hydrocortisone). The study reported here covers 4+ years, and is a follow-up of a previous study (West and Newns, 1955) . For the first 18 months the metabolites of cortisol were assayed by the "17-ketogenic steroid" (17 KGS) method (Norymberski, Stubbs, and West, 1953) and since then they have been assayed by the "total 17-hydroxycorticosteroid" (17(OH)CS) method (Appleby, Gibson, Norymberski, and Stubbs, 1955) . Both assays were developed at this Centre. The results of these two assays do not differ appreciably except in the rare disorders of the adrenal cortex. Consideration of the value and limitations of these assays will be referred to under the heading "Discussion" below but it can be stated at this point that a study of some 3,000 assays in conjunction with the clinical state of the patients concerned leaves no doubt that the anti-rheumatic effects produced by stimulating the adrenal cortex vary directly with the urinary output of 17 KGS and 1 7(OH)CS.
There have been many brief reports of the effects produced by corticotropin therapy and not a few describing undesirable effects, but rarely, if ever, 'have these reports included a statement of the level of adrenocortical stimulation achieved or of its duration. In view of the undesirable effects reported, this paper will take account of every * Part-time Nuffield Research Fellow, University of Sheffield. patient suffering from rheumatoid arthritis that has been treated here with corticotropin during the last 41 years.
Material
Patients.-These fell into two categories: (A) 44 patients who had completed a short course of therapy (3 to 6 weeks), the therapy in no case having been withdrawn because of ineffectiveness or complications. This group included patients receiving adrenal restimulation after prolonged oral corticosteroid therapy and patients with acute exacerbations of the disease not thought to be in need of prolonged therapy.
Those in the second category provided opportunities for the study of various preparations of corticotropin.
(B) 66 patients whose therapy either exceeds 3 months and continues to date or whose therapy has had to be withdrawn for one of the reasons to be stated.
42 of these patients ceased to receive therapy for the following reasons: The circumstances of these 42 withdrawals will be referred to again below.
Most of these 66 patients were considered in need of prolonged therapy since their disease had been aggressive and disabling for many months. At this Centre approximately one in every twenty rheumatoid arthritis patients was selected for prolonged adrenal stimulation or oral corticosteroid therapy (the latter therapy mainly for the purpose of controlled trials). Many of the severe cases had been referred from other hospitals, so that the percentage of hormone-treated patients from the general rheumatoid population will have been less than 5 per cent. In choosing severely affected patients for prolonged adrenal stimulation therapy, some further selection was inevitable. For prolonged therapy, patients have to have sufficient intelligence and facility to give themselves (or be given by a close relative) daily injections of corticotropin. Complicating diseases, such PROLONGED ADRENOCORTICAL STIMULATION as tuberculosis, chronic nephritis, and hypertension (save in two cases), excluded patients from this study.
Dosage.-For the last 4 years little corticotropin has been used other than Armour's High Purity Acthar Gel. This is an oxycellulose purified preparation. A dose large enough to raise the daily urinary output of 17 KGS or 17(OH)CS to from 20 to 35 mg. was given daily by intramuscular injection. The level aimed at varied with the severity of the disease and the clinical response. Frequent urinary assays were made until a steady therapeutic level was achieved. Thereafter assays were performed at least every 4 weeks, unless a change in the batch number of the corticotropin or an alteration in the clinical state of the patient called for additional assays to check the degree of adrenal stimulation.
Follow-up and Records.-Patients were seen at least every 4 weeks after discharge from hospital and a record was made of the following: Clinical state; weight; blood pressure; strength of grip; erythrocyte sedimentation rate; haemoglobin; packed cell volume; total white blood count; eosinophil count; 24-hr urinary excretion of 17 KGS or 17(OH)CS. For 2 years estimations of serum albumin and globulin, fibrinogen, and cholesterol were made, but these were not continued as they were not providing any useful additional information (the serum cholesterol levels did not rise).
The total white blood cell counts, which were found to rise roughly in proportion to the level of adrenal stimulation, will not be referred to further. The eosinophil counts were too variable to be of interest or value after the initial period of adrenal stimulation. The severity of the disease was the same in the women as in the men, and the outcome of therapy was the same for both sexes. When the results of this study are compared with those of other therapeutic studies, this unusual preponderance of men need not therefore be considered.
Findings
Before starting adrenal stimulation therapy, all the patients had received aspirin, 27 had had phenylbutazone, seventeen gold, and fourteen cortisone (see Table I , footnotes). Table I , which will be referred to repeatedly in the text, sets out the essential data for each patient, with the exception of the radiographic findings (Table VI) .
(1) EFFECT UPON THE DISEASE PROCESS.- Table I shows that the adrenal stimulation therapy given to these patients did not result in the eradication of the disease. This being so, it is necessary to compare the progress of these patients with that of a similar group who have not had adrenal stimulation therapy. The usual form of controlled trial was not possible and will remain impracticable until such time as we have corticotropin of a uniform potency which is not allergenic. (ii) Many previously untreated patients can have their physical ability improved by active physiotherapy alone (i.e. through some restoration of muscle power and through correction of deformity). Table I shows that in only one individual patient did the mean strength of grip (R+L) fall below the starting level. The fact that the last recorded figures are below the maximum figures is mainly due to the fact that the strength of grip is highest when the adrenal stimulation is highest, and a similar state of affairs is seen when the E.S.R., Hb, blood pressure, and weight records are studied. At some time during the study each patient will have been stimulated to a level well above his mean level. The mean level of 17 KGS or 17(OH)CS output for the last month of the entire group was 26 mg. and the mean of the means for the total duration of therapy was 28 mg. The only valid comparison for strength of grip is with the group of cortisonetreated patients referred to by West and Newns (1953) ; in this study the mean strength of grip of the 27 patients rose from 105/100 to 155/153 in the course of 19 months. This group had a mean disease duration of 6-1 years compared with 4-5 and 4-2 in this study. In 
ANNALS OF THE RHEUMATIC DISEASES
The findings in the other trials referred to previously do not provide comparable data except that of West and Newns (1953) . In that trial fifteen of twenty cortisone patients and twelve of twenty controls showed an advance in erosions over an average period of 19 months. As the difference between these findings and those of the present trial were so marked, the radiographs of the 1953 trial were reviewed. Those of nineteen patients were found and on re-reading them, using the same criteria as for the present study, the findings were as follows:
Ten of the nineteen had bony erosions of the hands at the start and twelve showed an advance in erosions and/or new erosions. Two others showed some loss of joint space.
In the Empire Rheumatism Council's AspirinCortisone Trial (1955) in a period of one year, the average number of joints radiologically affected for the first time was two per patient (joint narrowing and/or erosions were counted.)
In the Medical Research Council-Nuffield Foundation Cortisone versus Prednisone Trial (1957), ten of 24 cortisone patients and nine of 27 prednisone patients had evidence of advance in bone erosion at the end of one year. Both hand and foot radiographs were examined, but this did not double the number of patients showing an advance in erosions, since in most cases an advance in bone erosion of the hands was accompanied by similar changes in the feet (personal observation).
(2) OTHER EFFECTS (a) Blood Pressure.- Table VII (3) COMPLICATIONS.-During this 4j-year period of adrenal stimulation therapy, only one death occurred that was in any way related to therapy. This patient, who had suffered from severe rheumatoid arthritis for many years, was changed from delta-i cortisol (prednisolone) to adrenal stimulation therapy; she had a year previously acquired resistance to corticotropin but on this occasion was given a more purified preparation; she made a rapid and excellent response, but as rapidly re-acquired resistance, and although only "hypo-adrenal" for one day before cortisone was given she became psychotic and was transferred to a mental hospital where she died 5 days later.
Two other patients died in the course of the study. One had Simmonds' disease and rheumatoid arthritis; he relapsed severely on acquiring resistance to relatively crude corticotropin and was given delta-I cortisone (prednisone) instead; he died of a pulmonary embolus 6 months later and some evidence of polyarteritis was found at autopsy. The second was a patient whose rheumatoid arthritis was complicated by asthma; her treatment was changed to delta-i cortisol because of incipient congestive heart failure; she died of an overdose of a barbiturate a year later.
The much-discussed complications of corticosteroid therapy are peptic ulceration and its consequences, and less commonly severe, initially symptomless, bacterial infections. No such complications occurred during the 4j years of adrenal stimulation therapy. The therapy entailed many thousands of self-administered injections but only one abscess was seen.
Further complications referred to in accounts of corticosteroid and corticotropin therapy are:
(i) excessive loss of potassium to be prevented by giving potassium chloride;
(ii) a negative nitrogen balance due to protein catabolism which may be prevented by a high protein diet; (iii) loss of calcium leading to osteoporosis and compression fractures of vertebrae.
The patients in this study had no potassium chloride supplements, and pleased themselves as to what they ate. As a group they have more strength and more muscle than before therapy. No special study was made of the vertebral bone density, but the patient thought most likely to develop spinal osteoporosis (Patient 39, who has had more than 3 years of adrenal stimulation since her 68th birthday) has shown no radiological evidence of increased porosis.
The complications that did occur were as follows: (a) Acquired Sensitivity to Corticotropin.-Many patients acquired the ability to destroy the administered corticotropin, including oxycel-purified preparations, but few developed allergic manifestations. The subject has already been discussed fully (West, 1956 (e) Psychosis.-Two patients had psychotic episodes from which they recovered. I do not think that either episode would have occurred if the adrenal stimulation therapy had been better controlled.
Discussion
Before discussing the clinical effects of "adrenocortical stimulation therapy", some consideration of the nature of this therapy is relevant. It has consisted in the daily intramuscular injection of an extract of porcine or bovine pituitaries, usually in a gelatin medium. Biological assay suggests that 10 to 50 per cent. of the extract is "adrenocorticotropic hormone", and clinical study incriminates the remainder as the source of antigen responsible for inducing "acquired resistance" and allergic reactions (West, 1956 ). This remainder contains speciesspecific protein (unpublished finding), and could, theoretically, induce disease states other than local allergy and anaphylactic shock. Corticotropin with a purity comparable to re-crystallized insulin is desirable. There may be slight structural differences between the corticotropins in use-porcine, bovine, ovine, and cetacean-but there is as yet no evidence that they differ in their effects in man.
After parenteral administration, a variable amount of corticotropin reaches the adrenal where it promotes steroidogenesis and steroid secretion. Corticotropins may also have separate adrenocortical growth-promoting activity and fatmobilizing activity, but insufficient is known of these effects to include them in this discussion. From the evidence at present available, exogenous corticotropin (given to adults) promotes an increase in all the known steroids of the adrenal secretion with the exception of aldosterone. The secretion of aldosterone can be affected secondarily and in some cases perhaps primarily-the evidence so far accumulated is still fragmentary. When using the 17-ketogenic assay (which necessitates the assay of 17-ketosteroids) it is seen that the ratio of 17 KGS to 17 KS varies from patient to patient and may vary in the same patient from time to time. The significance of this is not known. It is possible that in some patients prolonged adrenocortical stimulation may result in a qualitatively abnormal secretion-this possibility has not yet been studied. As a result of adrenal stimulation therapy, the endogenous adrenocorticotropic hormone ceases to circulate and the usual diurnal rhythm of steroid secretion is replaced by a much greater rise and fall. Normally the adrenal secretion is lowest at night, whereas for most of the patients studied it has been highest at night. The reason for giving corticotropin in the evening is to assure a good night's sleep and a start to the day free from stiffness. In the late afternoon, when the steroid output falls and stiffness begins to return, the patients are better able to cope with the situation by keeping on the move or taking aspirin. A further matter to consider is the measure used for assessing the degree of adrenal stimulation. The urinary assay of 17 KGS and 17(OH)CS reflects quantitatively the adrenal output of cortisol (for a review of this subject see West, 1957) , but is this all we need to know? Clinically, at least for most patients, this measure of adrenocortical activity correlates very well with the therapeutic effects, but theoretically it may not measure the physiologically-active hormone (or hormones) available to the tissues. In those patients who develop hypertension or fluid retention (in the absence of renal or cardiac disease), it may be that there is a qualitatively different adrenal secretion not reflected by this measure of cortisol metabolites. It will be of interest to measure the adrenal output of aldosterone, corticosterone, and 11-desoxycortisol of these patients. Effect upon Rheumatoid Arthritis There are three major questions to be asked of this study:
(1) Has the adrenal stimulation therapy proved superior to oral cortisone therapy and if so why? (2) Do the advantages of this therapy outweigh the disadvantages? (3) If it is concluded that the therapy has favourably affected the course of the disease is this finding of aetiological significance? (1) Has the adrenal stimulation therapy proved superior to oral cortisone therapy, and if so why?
The answer to the first part of this question turns on the validity of the comparisons made between this study and the others referred to. It is generally agreed that the prognosis for early cases of rheumatoid arthritis is much better than that for cases of some years duration. This being so one would have expected this study group to have compared unfavourably with the M.R.C.-Nuffield Foundation aspirin-cortisone trial group (1955) But what of the future? Severe rheumatoid arthritis that has already lasted for several years usually grumbles on for a very long time. Can adrenal stimulation therapy be continued indefinitely ? Will the hypothalamicadenohypophyseal ACTH-producing mechanism return to normal after prolonged inactivity, and will normal function be adequate after years of living with a raised adrenocortical output of steroids? These questions remain to be answered. So far six patients have had continuous effective adrenal stimulation therapy for more than 3 years and are grateful for it. Patient 42, who is in her fifth year of treatment, remains in better health than she had been for many years before treatment began. For the 2 years before starting treatment she had to attend the eye department twice weekly for the treatment of iritis or corneal ulceration. She has not needed to return there since, though each evening when her injection is due her eyes begin to feel gritty.
(3) Have these findings any bearing on the aetiology of the disease?
It is commonly considered that the action of certain corticosteroids on rheumatoid arthritis is ANNALS OF THE RHEUMATIC DISEASES merely that of non-specific anti-inflammatory agents. This demonstration that adrenal stimulation therapy does favourably affect the course of severe rheumatoid arthritis without at the same time producing any demonstrable effects upon the course of the everyday inflammatory responses, occasioned by bacterial, viral, and physical agents, should put an end to this unhelpful and rather thoughtless assumption. This is not the place to engage in speculation as to the aetiology of the disease, but one is tempted to suggest that there may be a breakdown in a particular enzymic process, perhaps an inherited defect in response to an ubiquitous environmental agent, that an increased local concentration of cortisol may reverse. One might expect the physical and emotional stress of severe rheumatoid arthritis to stimulate the adrenal cortex (via the hypothalamus and pituitary) and to raise the level of cortisol in the tissues naturally, but it does not do so (West, 1957) . Is this in itself a defect?
The pattern of rheumatoid arthritis can vary so much that it is reasonable to assume that more than one agent is at work. The simplest concept is of local and humoral factors which may vary in relative importance from patient to patient. When the humoral factor is operative (? a low effective level of tissue cortisol) and the local factor not too gross, then adrenal stimulation therapy may reverse the defect.
Other Effects of Adrenal Stimulation Therapy
The adrenal cortex is the first of the endocrine glands to have been subjected to controlled stimulation for prolonged periods in man. The majority of the patients studied have started with a "normal" output of 17(OH)CS, have had that output doubled for a prolonged period, and appear to have received nothing but benefit. This naturally leads to the question whether a person's "normal" adrenocortical output is in fact his optimum output. Before this problem can be adequately tackled we shall need more reliable corticotropin and more comprehensive assay procedures for measuring just what steroids the adrenal cortex is producing.
The part that the adrenocortical secretions play in the causation of hypertension remains obscure. The level of blood pressure in untreated rheumatoid arthritics bears no relation to their output of 17(OH)CS (unpublished findings), and as can be seen from Table I the raising of the output of 17(OH)CS may or may not be associated with the production of hypertension. The question that these findings raise is whether the hypertension produced has resulted from a qualitatively abnormal secretion. As mentioned above, additional assay procedures are needed to answer this question-both for treated patients and in the case of Cushing's syndrome.
In the past, adrenocortical activity has been considered mainly in terms of gross deficiency and gross excess, with the Addisonian syndrome on the one hand, and on the other potassium depletion, sodium retention, protein catabolism, excessive fat deposition, osteoporosis, ulcerogenesis, and loss of response to infection. This is rather like considering the activity of insulin only in terms of hyper-and hypo-glycaemic coma. It is hoped that the findings of this study, in which electrolyte imbalance, protein catabolism, excessive fat deposition, osteoporosis, peptic ulceration, and lack of response to infection, have not accompanied increased adrenocortical activity, will promote more interest in physiological levels of adrenocortical activity. Summary An account is given of all the rheumatoid arthritic patients who have received adrenocortical stimulation therapy at this Centre during the past 4j years. Records are presented of the clinical and laboratory findings in 42 patients given continuous therapy, measured by urinary steroid assays, for from 3 to 50 months (average 16 mths). This group includes 22 patients treated for from 12 to 50 months (average 25 mths).
The results of the therapy are compared with the published results of controlled therapeutic trials in the treatment of rheumatoid arthritis. The nature of the therapy and its control are described and discussed and some of the implications of the findings are commented upon.
The following conclusions are drawn:
(1) That adrenocortical stimulation therapy, providing a daily urinary output of from 20 to 30 mg. 17(OH)CS, favourably affects the course of severe rheumatoid arthritis over prolonged periods in the majority of patients, and that in this respect it is superior to oral cortisone therapy.
(2) That the therapy described need not give rise to any serious side-effects or complications. That it does not, for instance, favour the development of peptic ulceration.
(3) That there is a wide range of adrenocortical activity between the clinically obvious extremes of Addison's disease and Cushing's syndrome, and that the effects of changes within this range warrant study in relation both to "normal" health and to disease states. 1, 1276. West, H. F. (1956) . Annals of the Rheumatic Diseases, 15, 124. (1957) . Ibid., 16, 173.
-and Newns, G. R. (1953) . Lancet, 2, 1123.
- (1955) . Ibid., 1, 578.
Effets de stimulation surrenocorticale prolongie sur des malades atteints d'arthrite rhumatismale
RMsUM
On fait un compte-rendu de tous les malades atteints d'arthrite rhumatismale et traits par la stimulation surrenocorticale dans ce Centre durant les derniers quatre ans et demi. On presente les rapports des resultats cliniques et de laboratoire chez 42 malades soumis au traitement continu, et mesure par leur excretion urinaire des steroides, pendant 3 a 50 mois (16 mois en moyenne). Ce groupe comprend 22 malades traits pendant 12 a 50 mois (25 mois en moyenne).
On compare les r6sultats de ce traitement avec les resultats publics d'essais contrdles. On decrit et discute la nature du traitement et ses methodes de contr6le et on commente quelques-unes des implications de ces resultats. On tire les conclusions suivantes:
(1) Le traitement de stimulation surrenocorticale produisant une excretion urinaire quotidienne de 20 a 30 mg. de 17-hydroxycorticosteroldes affecte favorablement le cours de l'arthrite rhumatismale severe, sur des periodes prolongees et chez la majority des malades, et est superieur sur ce point, au traitement par cortisone buccale.
(2) Le traitement decrit ne provoque pas necessairement d'effets secondaires serieux ou de complications. I1 ne favorise pas, par exemple, l'ulceration peptique.
(3) Il existe une large marge d'activite surrenocorticale entre les extremes cliniques evidents de la maladie d'Addison et du syndrome de Cushing et les effets des alterations a l'interieur de cette marge m6ritent des etudes aussi bien du point de vue de la sante "normale" que de l'etat morbide.
Efectos de estimulaci6n suprarreno-cortical prolongada sobre enfermos con artritis reumatoide SUMARIO Se relata aqui todos los casos de artritis reumatoide tratados por estimulaci6n suprarreno-cortical en este Centro durante los ultimos cuatro afnos y medio. Se presentan datos clinicos y de laboratorio respecto a 42 enfermos, sometidos a una terapia continua, controlada por determinaciones de esteroides urinarios, durante 3 a 50 meses (un promedio de 16 meses). Este grupo incluye 22 enfermos tratados durante 12 a 50 meses (un promedio de 25 meses).
Se comparan los resultados de este tratamiento con los resultados publicados de ensayos terapeuticos controlados en esta enfermedad. Se describe y se discute la naturaleza y los m6todos de control del tratamiento, y se anotan las implicaciones de los resultados. Se llega a las conclusiones siguientes:
(1) El tratamiento por estimulacion suprarrenocortical produciendo una excrecion urinaria diaria de 20 a 30 mg. de 17-hidroxocorticosteroides afecta favorablemente la evoluci6n de la artritis reumatoide severa, durante periodos prolongados y en la mayoria de los enfermos, y es superior, desde este punto de vista, a la cortisona por via oral.
(2) El tratamiento mencionado no provoca necesariamente efectos secundarios graves o complicaciones. Tampoco favorece, por ejemplo, la formaci6n de ulceras pepticas.
(3) Hay tun amplio margen de actividad suprarrenocortical entre los extremos clinicos obvios de la enfermedad de Addison y del sindrome de Cushing y los efectos de las alteraciones dentro de este margen merecen estudios ulteriores desde el punto de vista tanto de "normalidad" como de estado morbido.
